Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,763 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Grade Clear all
Completed Phase 1 Interventional Results available

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

NCT02083965
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04688164
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Relmada Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Miami, Florida • Miami Springs, Florida • Palm Bay, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 21, 2026, 9:05 AM EDT
Terminated No phase listed Observational

Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core

NCT03092687
View directory record Official record
Conditions
Schizophrenia, Major Depression, Bipolar Disorder, PTSD
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Up to 120 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02905331
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

NCT03352453
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 21, 2026, 9:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions
GTAEXS617, SoC
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cellular Aging and Neurobiology of Depression Study

NCT00285935
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Standard Clinical Care with an SSRI
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 60 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 21, 2026, 9:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
74
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 9:05 AM EDT
Completed No phase listed Observational

Neurophysiology and Anatomy of Severe Intraventricular Hemorrhage (IVH)

NCT00817310
View directory record Official record
Conditions
Intracranial Hemorrhages, Prematurity
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 14 Days
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 21, 2026, 9:05 AM EDT
Active, not recruiting Phase 1 Interventional

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

NCT05835687
View directory record Official record
Conditions
Central Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, High Grade Glioma, Glioblastoma, Medulloblastoma
Interventions
B7-H3-CAR T cells
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 9:05 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

NCT00266214
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
lidocaine patch 5%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Food Effect Study of LY03005

NCT03822065
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

NCT01262365
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

NCT00001034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 9:05 AM EDT
Recruiting Phase 1 Interventional

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

NCT05686798
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
Interventions
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Not applicable Interventional

The Effect of Resistance to Participant-Supported Reaching on Workspace of the Hand in Severe Chronic Stroke

NCT01548781
View directory record Official record
Conditions
Stroke
Interventions
Impairment-based robotic intervention for reaching function
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 21, 2026, 9:05 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

NCT06018428
View directory record Official record
Conditions
Alopecia Areata
Interventions
bempikibart (ADX-914)
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 21, 2026, 9:05 AM EDT
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 1Phase 2 Interventional

Cognitive Training for Depression

NCT01936506
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Training A, Cognitive Training B
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 21, 2026, 9:05 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Treatment of Severe Hypertension With ICG Directed Therapy

NCT04748107
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Impendence Cardiography
Diagnostic Test
Lead sponsor
Marshall University
Other
Eligibility
15 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pemetrexed in Children With Recurrent Cancer

NCT00520936
View directory record Official record
Conditions
Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease), Neuroblastoma (Metaiodobenzylguanidine, Positive Evaluable), Rhabdomyosarcoma, Ependymoma, Non-brainstem High-grade Glioma
Interventions
pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 22 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

NCT00047021
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
sargramostim, cytarabine, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 21, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01071252
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
San Diego, California • Louisville, Kentucky • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 21, 2026, 9:05 AM EDT